Targeted agents have significantly improved outcomes for patients with chronic lymphocytic
leukemia, particularly high-risk subgroups for whom chemoimmunotherapy previously …

Even if treatment options for Chronic Lymphocytic Leukemia (CLL) patients have changed
dramatically in the past few years, with the approval of targeted therapeutic agents, the …

Agents that specifically target pathologic mechanisms of survival have now been approved
for the treatment of chronic lymphocytic leukemia in both the treatment-naive and …

Simple Summary Nowadays, many patients with chronic lymphocytic leukemia (CLL) are
treated with so-called novel agents, including BTK inhibitors, Bcl-2 inhibitors and PI3K …

Therapy for chronic lymphocytic leukemia has improved dramatically over the past decade
with the introduction of new targeted therapies and a paradigm shift toward targeted …

The treatment of chronic lymphocytic leukemia (CLL) embodies one of the great success
stories in translational research, with the development of therapies aimed at disrupting …

The first-line treatment of chronic lymphocytic leukemia (CLL) has evolved significantly in the
past 5 years with the introduction of oral novel targeted therapies ibrutinib and acalabrutinib …

The treatment of chronic lymphocytic leukaemia has been revolutionised in recent years, first
by the introduction of chemoimmunotherapy regimens and subsequently by the …

Abstract Purpose of Review Over the last years, targeted anticancer therapy with small
molecule inhibitors and antibodies has much replaced chemoimmunotherapy, which has …

Introduction: In recent years, innovative mechanism-based drugs have enriched the
therapeutic armamentarium for patients with chronic lymphocytic leukemia (CLL) and are …